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1,4-dihydropyridine (DHP) calcium channel antagonists
bind with very high affinity (0.1-5 nM) to specific mem-
brane-associated receptors in cardiac sarcolemma (1).
Several characteristics of the canine cardiac sarcolemmal
membrane and drugs that bind to receptors in this mem-
brane (2, 3) suggest that it is appropriate to consider a
two-stage binding mechanism that involves partitioning of
the drug molecule into the lipid bilayer, where it may
become oriented and then diffuse laterally to a receptor
binding site.
To define the molecular properties of cardiovascular
drugs in membranes, it is helpful to have a molecular
picture of the drug directly determined in its natural
environment. We have used x-ray and neutron diffraction
techniques with both model and native biological mem-
branes to determine the position, orientation, and confor-
mation of a d adrenergic antagonist (propranolol) and a
DHP calcium channel antagonist (nimodipine) in a mem-
brane bilayer. These results are being combined with
previous studies to establish a molecular mechanism for
the binding of drugs to their receptors in the heart.
Several previous observations from cardiac sarcolem-
mal membrane suggest that the membrane bilayer is
important in drug binding to cardiac receptors. Colvin et
al. (2) have demonstrated that receptor site densities
(sites/,Am2) in sarcolemma are quite low for some ligands:
ouabain, 330; quinuclidinyl benzilate, 5; dihydroalprenolol,
2; nitrendipine, 1. Herbette et al. (3) have demonstrated,
using x-ray diffraction, that the structure of this mem-
brane resembles that of a pure lipid bilayer, as might be
expected from the high lipid-to-protein ratio (3 ,uM phos-
pholipid/mg protein). X-ray and neutron diffraction have
been used to determine the precise location of propranolol
(4) and the DHP Bay P 8857 in model -membranes. The
naphthalene moiety of propranolol and the five-substituent
side chain of Bay P 8857 are both located within the first
few methylene segments of the fatty acyl chains in these
bilayers. That partition coefficients determined for these
antagonists in the membrane' Table I) are significantly
higher than those obtained in octanol/buffer indicates the
'Membrane partition coefficients were determined in sarcoplasmic reticu-
lum in order to reflect only nonspecific drug binding.
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necessity to understand drug-membrane interaction at the
molecular level. In addition, Bay P 8857 and nimodipine
had intrinsic binding rates of 3 x I07 and 1 x 107 (Ms)-1,
at 250C. Nonspecific binding of these drugs to membranes
without specific receptors appeared to be at least 1,000
times faster than specific binding. These experimental
rates of binding can now be evaluated in light of recent
theoretical diffusion-limited rates in which drug binding to
sarcolemmal receptors via the membrane bilayer is at least
1,000 times faster than an aqueous pathway approach (5).
We describe here some structural measurements under-
taken to explore further the possibility that partitioning of
these drugs into the lipid bilayer matrix of receptor
containing membranes is necessary for binding of these
drugs to cardiac membrane receptors.
RESULTS AND DISCUSSION
X-ray crystallography was used to determine the crystal
structures of propranolol and nimodipine (Fig. 1). The
propranolol molecule is nearly planar with the charged
amine group 5.5 A from the center of mass of the
naphthalene moiety. The crystal structure of nimodipine
was similar to that of other DHP calcium channel antago-
nists (6) with the planes of the nitrophenyl and pyridine
rings approximately perpendicular and the pyridine ring
slightly puckered.
Neutron diffraction studies showed that the center of
TABLE I
PARTITION COEFFICIENTS
Drug* Biological Octanol/BuffertMembranes
Bay P 8857 125,000 42
Nisoldipine 6,000 38
Nimodipine 5,000 730
Propranolol 200 18
Acetylcholine 32 0.003
Timolol 16 0.7
Ethanol 3 0.6
*Bay P 8857, Nisoldipine and Nimodipine are DHP calcium channel
antagonists; Propranolol and Timolol are beta adrenergic antagonists.
tBuffer was 150mM NaCl, 10 mM Tris/Cl, pH 7.2.
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FIGURE 1 Crystal structure of (a) propranolol and (b) nimodipine as determined by x-ray crystallographic methods. (c) Placement of the
crystal structure of propranolol in a membrane bilayer as suggested by neutron diffraction. Please refer to the color figure section at the back
of this book.
mass of the naphthalene moiety of propranolol is located
-10 A from the bilayer surface, in the region of the first
few methylene segments of the fatty acyl chains. Because
water penetrates the headgroup region only up to the
glycerol backbone, the naphthalene moiety of propranolol
is in a region of the bilayer where water is excluded. With
the crystal structure of propranolol superimposed on the
structure of a lipid bilayer, and positioned as determined
by neutron diffraction, the charged amine lies within the
phospholipid headgroup region, where it could be involved
in ionic interactions.
Neutron diffraction was used to determine the nonspe-
cific binding location of deuterated nimodipine (pyridine:
2,6-CD3) in the sarcoplasmic reticulum. The difference
profile demonstrated that nimodipine was located in the
protein knob region and at both water/hydrocarbon core
interfaces of the bilayer, with more drug appearing in the
inner monolayer. Its position near the water/hydrocarbon
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FIGURE 2 (a) A drug L may reach a binding site S1 or S2 on a
membrane associated receptor protein (R) by I direct diffusion through
the aqueous solvent or by 2 partitioning into the lipid bilayer and then
diffusing laterally to the active site. (b) The highly ordered strucutre of
the lipid bilayer may restrict membrane soluble drugs to a particular
depth of penetration into the bilayer (drugXwould be a reactive molecule
since it is positioned at the proper depth of penetration for optimal
reaction with a protein receptor site, drug Y would be inactive). (c)
Bilayer constraints on the orientation of drug molecules relative to the
active site might also affect their activity (drug Xwould be active, drug Y
would be inactive).
core interface in the membrane bilayer is similar to that of
propranolol's naphthalene ring. Although the location of
the nitrophenyl ring of nimodipine has not been deter-
mined in the membrane bilayer, the crystal structure (Fig.
1 b) suggests that it would be positioned within the hydro-
carbon core region of the bilayer. Because the nimodipine
was added externally to sealed sarcoplasmic reticulum
vesicles, this neutron diffraction experiment also demon-
strated that these drugs can flip-flop, that is, diffuse
between monolayers of the same membrane bilayer. That
more nimodipine was found in the inner monolayer is
consistent with the observation that the inner monolayer
contains -8% more lipid than the outer monolayer (7).
These results demonstrate that (a) these drugs bind non-
specifically to both protein and lipid components of the
membrane; (b) the molar ratio of drug:lipid is the same for
both monolayers; and (c) these drug substances can cross
the membrane bilayer of biological membranes.
CONCLUSIONS
X-ray and neutron diffraction together can define the
precise location, conformation, and orientation of drug
molecules in model and biological membranes and, when
combined with other techniques, can provide valuable
information for elucidating the mechanism of drug-recep-
tor interactions. These techniques were used in the present
study to determine whether the nonspecific interaction of
certain cardiovascular drugs with the membrane bilayer is
a component of the pathway by which these drugs reach
specific protein receptors. Although the model needs fur-
ther testing, it is supported by recent patch-clamp studies
carried out with cultured cardiac cells (8). Knowledge of
the structure of the drug when it nonspecifically incorpo-
rates into the membrane bilayer and when it binds to its
receptor may help us to understand the molecular basis for
how these drugs function to alleviate a particular cardio-
vascular abnormality. This understanding may help estab-
lish essential molecular criteria (see Fig. 2) for the design
of new drugs that are more potent in action, more selective
for binding to specific receptors, and that function with
fewer side effects.
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Gangliosides are anionic glycolipids that are found in the
outer monolayer of many plasma membranes. In particu-
lar, the polar head group of ganglioside GM, plays an
important role in human physiology as it is the receptor for
cholera toxin (1) and it regulates growth factor receptors
(2). Gangliosides will not form bilayers by themselves,
presumably because their head groups are large (3-5).
However, multilamellar liposomes formed from mixtures
of phosphatidylcholine (PC) and GM, (4) have been used as
models of the electrokinetic properties of human erythro-
cyte membranes (6). In this report, the structure of
PC:GM, liposomes is analyzed by x-ray diffraction tech-
niques to determine the distance by which the polar head
group of GM, extends from the bilayer surface. We label
the sialic acid moiety of GM, with europium (Eu) (5) and
use difference profiles to determine the distance between
the fixed charge on GM, and the phosphate group of PC.
MATERIALS AND METHODS
We formed bilayers from a 7:3 mol:mol mixture of 1-palmitoyl-2-oleyl
phosphatidylcholine (PC) with GM,. PC was purchased from Avanti Polar
Lipids, Inc. (Birmingham, AL). GM, (>90% by TLC) was prepared from
upper Foich extract of bovine brain (7). Eu-labeled GM, was prepared by
adding 1 mol europium chloride/mol GM, in methanol:water 33:1,
followed by evaporation of solvent. Europium chloride (99.9%) was
obtained from Alfa Inorganics, Inc. (Beverly, MA). Swelling experiments
were performed by gravimetrically adding dry lipid to increasing amounts
of aqueous 0.1 M NaCl, pH 7.5. The x-ray patterns were recorded and
analyzed by standard techniques, as described previously (8).
RESULTS
For a range of water contents of l15-50 wt %, each
diffraction pattern contained five or six orders of a single
lamellar repeat period and a broad wide-angle band at 4.6
A, indicating a single multilamellar phase of liquid crystal-
line bilayers. We obtained lamellar repeat periods of 62-70
A for unlabelled bilayers and 62-78 A for Eu-labelled
bilayers. At repeat periods larger than this range, only two
or three lamellar diffraction orders were recorded. At
repeat periods smaller than this range, phase separation
(4) resulted, as indicated by additional low-angle reflec-
tions that did not index on the lamellar repeat period, as
well as an additional sharp wide-angle reflection at 4.2 A
(3). The points in Fig. 1 indicate the observed structure
amplitudes. The curves in Fig. 1 are derived from a
sampling theorem analysis and are proportional to the
absolute value of the Fourier transform of the electron
density distribution across the PC:GMl bilayer. The two
transform curves are similar in shape, indicating that the
Eu label did not drastically alter the bilayer structure. The
correct phase angle, either ir or 0, was assigned to each
region of the transforms by using the sampling theorem
(8). The resulting electron density profiles are shown in
Fig. 2. The top profile is of a bilayer labelled with Eu and
the middle profile is of an unlabelled bilayer. The Eu
difference profile (bottom of Fig. 2) was obtained by
subtracting the scaled unlabelled profile from the labelled
profile, with a scaling factor that assumes no penetration of
Eu ions into the hydrocarbon region of the bilayer (5). The
Eu Labelled
E
,R t\ Unlabelled
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FIGURE 1 Structure amplitudes for a series of swelling experiments for
unlabelled and europium-labelled PC:GMI multilayers. The smooth
curves were calculated using the sampling theorem.
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